Ute I. Schwarz
Ute I. Schwarz
Unknown affiliation
Verified email at
Cited by
Cited by
Identification of functionally variant MDR1 alleles among European Americans and African Americans
RB Kim, BF Leake, EF Choo, GK Dresser, SV Kubba, UI Schwarz, ...
Clinical Pharmacology & Therapeutics 70 (2), 189-199, 2001
Genetic determinants of response to warfarin during initial anticoagulation
UI Schwarz, MD Ritchie, Y Bradford, C Li, SM Dudek, A Frye-Anderson, ...
New England Journal of Medicine 358 (10), 999-1008, 2008
Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine
GK Dresser, DG Bailey, BF Leake, UI Schwarz, PA Dawson, DJ Freeman, ...
Clinical pharmacology & therapeutics 71 (1), 11-20, 2002
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
GM Cooper, JA Johnson, TY Langaee, H Feng, IB Stanaway, UI Schwarz, ...
Blood, The Journal of the American Society of Hematology 112 (4), 1022-1027, 2008
Intestinal drug transporter expression and the impact of grapefruit juice in humans
H Glaeser, DG Bailey, GK Dresser, JC Gregor, UI Schwarz, JS McGrath, ...
Clinical Pharmacology & Therapeutics 81 (3), 362-370, 2007
Identification and functional characterization of a new CYP2C9 variant (CYP2C9* 5) expressed among African Americans
LJ Dickmann, AE Rettie, MB Kneller, RB Kim, AJJ Wood, CM Stein, ...
Molecular pharmacology 60 (2), 382-387, 2001
MDR1 Gene Polymorphisms Affect Therapy Outcome in Acute Myeloid Leukemia Patients
T Illmer, US Schuler, C Thiede, UI Schwarz, RB Kim, S Gotthard, D Freund, ...
Cancer research 62 (17), 4955-4962, 2002
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects
GK Dresser, UI Schwarz, GR Wilkinson, RB Kim
Clinical Pharmacology & Therapeutics 73 (1), 41-50, 2003
Clinical relevance of genetic polymorphisms in the human CYP2C9 gene
UI Schwarz
European journal of clinical investigation 33, 23-30, 2003
Human skeletal muscle drug transporters determine local exposure and toxicity of statins
MJ Knauer, BL Urquhart, HE Meyer zu Schwabedissen, UI Schwarz, ...
Circulation research 106 (2), 297-306, 2010
Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants
RH Ho, L Choi, W Lee, G Mayo, UI Schwarz, RG Tirona, DG Bailey, ...
Pharmacogenetics and genomics 17 (8), 647, 2007
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
UI Schwarz, T Gramatté, J Krappweis, R Oertel, W Kirch
International journal of clinical pharmacology and therapeutics 38 (4), 161-167, 2000
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care
MK DeGorter, RG Tirona, UI Schwarz, YH Choi, GK Dresser, N Suskin, ...
Circulation: Cardiovascular Genetics 6 (4), 400-408, 2013
Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception
UI Schwarz, B Büschel, W Kirch
British journal of clinical pharmacology 55 (1), 112, 2003
Grapefruit juice ingestion significantly reduces talinolol bioavailability
UI Schwarz, D Seemann, R Oertel, S Miehlke, E Kuhlisch, MF Fromm, ...
Clinical Pharmacology & Therapeutics 77 (4), 291-301, 2005
Induction of intestinal P‐glycoprotein by St John's wort reduces the oral bioavailability of talinolol
UI Schwarz, H Hanso, R Oertel, S Miehlke, E Kuhlisch, H Glaeser, M Hitzl, ...
Clinical Pharmacology & Therapeutics 81 (5), 669-678, 2007
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe
BL Urquhart, JA Ware, RG Tirona, RH Ho, BF Leake, UI Schwarz, H Zaher, ...
Pharmacogenetics and genomics 18 (5), 439, 2008
Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters
MG Mooij, UI Schwarz, BAE De Koning, JS Leeder, R Gaedigk, ...
Drug Metabolism and Disposition 42 (8), 1268-1274, 2014
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy
IY Gong, RG Tirona, UI Schwarz, N Crown, GK Dresser, S LaRue, ...
Blood, The Journal of the American Society of Hematology 118 (11), 3163-3171, 2011
Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation
IY Gong, UI Schwarz, N Crown, GK Dresser, A Lazo-Langner, GY Zou, ...
PloS one 6 (11), e27808, 2011
The system can't perform the operation now. Try again later.
Articles 1–20